Pharmaceutical

Opinion: What the hospital-at-home movement tells us ab...

Why did wider adoption of hospital-at-home hospital strategies have to wait for ...

Kellogg’s is going to war over Mexico’s nutrition label...

Kellogg’s is desperate to save Tony the Tiger and Toucan Sam from Mexico’s healt...

STAT+: As the obesity drug market grows, digital health...

Payers are reeling as they try to figure out how to sustainably cover new obesit...

STAT+: An innovative eye stem cell transplant could hel...

Prior to the transplant, dealing with constant eye pain and loss of vision, the ...

STAT+: Pharmalittle: Weight loss drugs cost much more i...

A U.S. appeals court struck down key parts of an Oklahoma law designed to regula...

Why so few get screened for lung cancer, the deadliest ...

A combination of strict eligibility criteria and special requirements for insura...

ProMED sees offers of support, but its future remains u...

With its future in doubt, ProMED, the financially strapped infectious diseases s...

Having celiac disease and a thyroid condition sent her ...

“We like being included. One of my love languages or manifestations of my love l...

Opinion: Medicine robs physicians of their fertility. H...

The often-irreversible damage experienced by physicians and medical students who...

EMA accepts for review Iveric Bio’s MAA for geographic ...

Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary ...

Nuvectis receives orphan drug designation for cholangio...

Nuvectis Pharma has received US Food and Drug Administration (FDA) orphan drug d...

US Appeals court rules in favour of further abortion pi...

The US Circuit Court of Appeals restricted the prescription of abortion pills, f...

AbbVie achieves win for migraine prevention drug Aquipt...

The decision brings the first daily oral migraine prophylactic to Europe, with p...

Boehringer Ingelheim advances weight loss drug to Phase...

Depending on Phase III results, survodutide could soon enter the weight loss mar...

Imugene licenses potential first-to-market allogeneic C...

Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has show...

Signal: Abortion pill restriction may drive more patien...

As restrictions on abortion drug mifepristone loom, doctors and patients are loo...